chronic gout epidemiology forecast insight

DelveInsight’s ‘Chronic Gout–Epidemiology Forecast—2034’ report delivers an in-depth understanding of the Chronic Gout, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Chronic Gout Disease Understanding

Gout is a chronic disease caused by monosodium urate (MSU) crystal deposition. Gout typically presents as an acute, self-limiting inflammatory monoarthritis that affects the joints of the lower limb. Elevated serum urate level (hyperuricemia) is the major risk factor for MSU crystal deposition and the development of gout. Although traditionally considered a disorder of purine metabolism, altered urate transport, both in the gut and the kidneys, has a key role in the pathogenesis of hyperuricemia (Dalbeth et al., 2021).

Gout distinguished itself in the history of Homo sapiens since time immemorial. It appeared in medical records very early in the history of medical writing and was also mentioned in the biographies of many famous names. It was depicted as the fate of a life of affluence as much as the challenge to a physician’s skill, and truly it was. Modern ages witnessed remarkable progress in managing gout. More recently, thanks to quantum leaps in molecular biology, diagnostic modalities, and pharmacotherapy, we enjoy a deeper understanding of the disease and a more sophisticated armamentarium (Ragab et al., 2017).

Gout is one of the few rheumatological diseases that can be cured. Multiple pertinent guidelines and treatment recommendations have been published, but there is reason to believe that patients with gout are not always treated accordingly. The prevalence of gout is rising around the world. Patients with gout could benefit greatly from consistent implementation of the existing treatment guidelines and recommendations (Engel et al., 2017).

Gout is divided into four stages: Asymptomatic deposits in tissues, acute gout, Intercritical periods, and chronic gout.

Acute gout: This is defined as rapidly-developing inflammation, usually of only one joint, with painful overheating and swelling. Uric acid crystals trigger the inflammation reaction in joints or tissues around joints.

Intercritical periods: These are clinically inactive disease phases between two flares. During these periods, gout patients also have hyperuricemia, leading to increased deposition of urate crystals in tissues. Intercritical periods become shorter as the disease progresses.

Chronic gout: This is characterized by long-term joint inflammation, which leads to joint pain at rest and on movement.

MSU crystals can be deposited in all tissues, mainly in and around the joints forming tophi. Gout is mainly diagnosed by identifying the pathognomonic MSU crystals by joint fluid aspiration or in tophi aspirate. Early presentation of gout is an acute joint inflammation that is quickly relieved by NSAIDs or colchicine. Renal stones and tophi are late presentations. Lowering SUA levels below the deposition threshold either by dietary modification and using serum uric acid lowering drugs is the main goal in the management of gout. This results in the dissolution of MSU crystals preventing further attacks (Ragab et al., 2017).

Gout is one of the most common causes of chronic inflammatory arthritis in the United States, which is characterized by monosodium urate (MSU) monohydrate crystals deposition in the tissues. Gout was first recognized even before the Common Era. Hence it is arguably the most understood and manageable disease amongst the other rheumatic diseases. This activity reviews the evaluation and management of gout and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes (Fenando & Widrich, 2021).

The 2007–2008 data from NHANES revealed that 8.3 million Americans are affected by gout, of which 71% had CKD stage greater than stage 2 (GFR < 60). The prevalence of CKD stage 3 or greater in gout was 19.9%. The inclusion of proteinuria in the definition of CKD has led to the investigation of the prevalence of gout in patients with proteinuria. Lowering serum uric acid levels to less than 6mg/dl in CKD patients with gout tends to reduce acute gouty flares. The presence of CKD does not alter the need to reach this goal; however, levels less than 5 mg/dL may be more appropriate in advanced diseases (Ahmed and Bailey, 2016).

In addition, many biopharmaceutical companies are also trying to develop biologics for the treatment of Gout disease. This would develop an opportunity for the global Gout disease treatment market. Some major companies operating in the global Gout disease treatment market are Takeda Pharmaceutical Company, Novartis, Pfizer, and Merck.

Numerous risk factors for the development of gout have been established, including hyperuricaemia, genetic factors, dietary factors, alcohol consumption, metabolic syndrome, hypertension, obesity, diuretic use and chronic renal disease.

Common medications include nonsteroidal anti-inflammatory drugs and corticosteroids, another anti-inflammatory. These reduce swelling and pain in the areas affected by gout.

Chronic Gout Epidemiology

The Chronic Gout epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Gout epidemiology segmented as the Total Prevalent Cases of Gout, Total Prevalent Cases of Chronic Gout, Gender-specific prevalent cases of Chronic Gout, Prevalence of Chronic Gout based on Risk factors. The report includes the prevalent Chronic Gout scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country Wise- Chronic Gout Epidemiology

The epidemiology segment also provides the Chronic Gout epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• The total prevalent population of Chronic Gout associated in 7MM countries was estimated to be 2,380,641 cases in 2020 and expected to increase at a CAGR of 0.24% for the study period, i.e., 2021-2034.
• Among the EU5 countries, UK had the highest prevalent population of Chronic Gout. On the other hand, France had the lowest number of case, 71,610 cases in 2020.

Scope of the Report

• Chronic Gout report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
• Chronic Gout Epidemiology Report and Model provide an overview of the risk factors and global trends of Chronic Gout in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Chronic Gout in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM concerning the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Chronic Gout
• The report provides the segmentation of the Chronic Gout epidemiology by prevalent Cases of Chronic Gout in 7MM
• The report provides the segmentation of the Chronic Gout epidemiology by Prevalence of Chronic Gout, Prevalence of Chronic Gout based on Etiology specific factors, Age-specific cases of Chronic Gout in 7MM

Report Highlights

• 10-year Forecast of Chronic Gout  epidemiology
• 7MM Coverage
• Total Prevalent Cases of Chronic Gout
• Prevalent Cases of Chronic Gout based on Gender
• Prevalent Cases of Chronic Gout based on Comorbidities
• Prevalence of Chronic Gout based on Age

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM concerning the patient population about Chronic Gout?
• What are the key Findings of Chronic Gout epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2025-2034)?
• What would be the total number of patients with Chronic Gout across the 7MM during the forecast period (2025-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?
• What are the disease risk, burden, and unmet needs of Chronic Gout?
• What are the currently available treatments for Chronic Gout?

Reasons to buy

The Chronic Gout Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Chronic Gout  market
• Quantify patient populations in the global Chronic Gout market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Chronic Gout therapeutics in each of the markets covered
• Understand the magnitude of Chronic Gout population by its prevalent cases
• Understand the magnitude of Chronic Gout population by its clinical manifestation specific cases
• The Chronic Gout epidemiology report and model was written and developed by Masters and PhD level epidemiologists
• The Chronic Gout Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population